Close Menu

NEW YORK (360Dx) – Opko Health announced today that it has received US Food and Drug Administration approval for its point-of-care Sangia Total Prostate Specific Antigen (PSA) Test using the company's Claros 1 Analyzer.

The test quantitatively measures total PSA in whole blood from a fingerstick of blood collected by a healthcare professional. It is used in conjunction with a digital rectal exam as an aid in the detection of prostate cancer in men aged 50 years or older. There are 25 million PSA tests performed in the US annually, according to Opko.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.